Post-Cutoff.com
  1. Home
  2. Timeline
  3. 2025
  4. FutureHouse's Robin multi-agent system proposes ripasudil…

FutureHouse's Robin multi-agent system proposes ripasudil as a new treatment candidate for dry AMD

★★★scienceFutureHouseconfidence: high

FutureHouse's Robin generated the hypotheses, analyses and figures that identified ripasudil, a glaucoma drug, as a candidate for dry age-related macular degeneration. Ripasudil increased phagocytosis in retinal pigment epithelium cells and upregulated ABCA1 about 3×. Humans ran the bench work; the project took 2.5 months. Published in Nature on 19 May 2026.

Key facts

Science result

Field
medicine / ophthalmology / drug repurposing
Problem
Treatments for dry age-related macular degeneration
Result
AI-generated hypothesis that ripasudil enhances RPE phagocytosis, confirmed in cell assays.
AI system
Robin (Crow, Falcon, Finch agents)
Human role
AI-assisted: AI generated hypotheses and analyses; humans ran experiments
Verification
Peer-reviewed in Nature (2026); lab-validated in vitro
Status
confirmed

What happened

Robin chained literature-search and data-analysis agents to go from disease to mechanism to drug candidate, with human lab work in between.

Why it matters

It was an early end-to-end AI-driven discovery loop in biology. The overstated effect size is a reminder that AI analyses need human re-checking.

Changelog

  • 2026-09-29: created

Related events

  1. Google's AI co-scientist independently reproduces an unpublished superbug discovery in 48 hours ★★★★
  2. Edison Scientific's Kosmos AI scientist claims six months of research per run ★★★
  3. Google launches 'Gemini for Science' at I/O 2026: Co-Scientist, AlphaEvolve and ERA become products ★★★

Sources (2)

id: 2025-05-20-futurehouse-robin-ripasudil · updated 2026-09-29 · open in the interactive timeline